Editorial Board

Interested in reviewing for the journal? Email the editorial office.

EDITOR-IN-CHIEF
	Justo P Castaño, PhD Professor of Cell Biology, Head of the Hormones and Cancer Research Group, Maimonides Biomedical Research Institute of Cordoba, Reina Sofía University Hospital and University of Cordoba, Spain Justo P Castaño is a translational researcher on endocrine oncology. His team investigates the cellular and molecular basis of neuroendocrine tumors (NETs), pituitary tumors and pancreatic adenocarcinoma, and the role of metabolic and hormonal alterations in cancer. Their discovery of aberrant splicing variants of neuropeptides (eg In1-ghrelin) and receptors (eg SST5TMD4) led to focus their research on the emerging pathophysiologic and oncogenic role of the dysregulation of RNA biology and surveillance mechanisms, particularly alternative splicing, in endocrine tumors and cancer. Their integrative approaches include from molecular 'omics' and bioinformatic methods to in vitro and preclinical studies.
DEPUTY EDITOR
	Simona Glasberg, MD Director, Neuroendocrine Tumor (NET) Unit, ENETS Center of Excellence, Endocrinology and Metabolism Department, and Associate Professor of Endocrinology, Hadassah Medical Organization and Faculty of Medicine, the Hebrew University of Jerusalem, Israel A specialist in endocrinology and internal medicine, Simona completed a fellowship in NETs and Endocrine Oncology at St Bartholomew’s Hospital & William Harvey Research Institute, London, UK, exploring the mechanisms by which somatostatin analogues regulate the growth of NETs and their interaction with mTOR inhibitors. One of the foremost experts in the diagnosis and management of NETs in Israel, Simona is actively involved in the care of patients as well as in the research in the field. Her research interest is translational ranging between clinical studies in NETs and basic research focused on revealing the mechanisms of NETs cell proliferation and overcoming drug resistance.
ASSOCIATE EDITORS
	Charlotte Lynne Bevan, PhD Professor of Cancer Biology, Deputy Head of Division of Cancer, Imperial College, UK Charlotte Bevan’s research is focussed on mechanisms of androgen signalling and its role in development and disease. This began during her PhD at the University of Cambridge which was concerned with androgen insensitivity syndrome, a paediatric condition. Since then she has largely focussed on prostate cancer and her teams’ specific interests include: mechanisms of androgen signalling leading to prostate (and breast) cancer growth; identification of key genes, proteins, nucleic acids involved in the androgen response; mechanisms of escape from hormonal control of prostate tumours; new approaches to inhibit androgen receptor in resistant cases; functional interactions between different nuclear receptors in cancer progression and therapy response; the role of the microenvironment in progression.
	C Elizabeth Caldon, PhD Group Leader, Replication and Genome Stability Group, Garvan Institute, Australia Associate Professor Liz Caldon runs a basic and translational research program on estrogen receptor positive (ER+) breast cancer and basal-like breast cancers. Her group has built models of hormone therapy and CDK4-6 inhibitor resistance to understand the evolution of ER+ breast cancers as they become refractory to standard of care therapies. Specific interests of her group are the understanding of tumour cell evolution through single cell modelling, cell cycle based therapies, therapy repurposing, and the development of targeted approaches in therapy resistant disease.
	Ruth Casey, MB, PhD Consultant Endocrinologist, Cambridge University Hospital, UK Dr Ruth Casey is a Consultant Endocrinologist in Cambridge University Hospital NHS Foundation Trust and holds an academic position as a senior research associate in the Department of Medical Genetics, Cambridge University. Dr Casey leads neuroendocrine tumour (NET) and endocrine cancer services in Cambridge and is the endocrine lead for the endocrine genetics service, encompassing both clinical practice and independently funded research in GIST, phaeochromocytoma and paraganglioma. She has a specialist research interest in SDH deficient tumours and the molecular mechanisms underpinning endocrine cancers.
	Ben Challis, MD, PhD Honorary Consultant in Endocrinology, Addenbrooke’s Hospital; Head of Translational Science and Experimental Medicine, AstraZeneca, Cambridge, UK Dr Ben Challis is an Honorary Consultant in Endocrinology at Addenbrooke’s Hospital, Cambridge University Hospitals Foundation Trust, Cambridge, UK. He is also Head of Translational Science & Experimental Medicine in the Cardiovascular, Renal and Metabolism Biopharmaceutical R&D at AstraZeneca. Dr Challis’ research interests include neuroendocrine tumours, inherited tumour syndromes and metabolic disease.
	Scott M Dehm, PhD Professor and Apogee Enterprises Chair in Cancer Research, Departments of Laboratory Medicine and Pathology and Urology, and the Masonic Cancer Center, University of Minnesota, USA Professor Dehm's research is focused on understanding how alterations in the genome, transcriptome, and proteome of prostate cancer cells underlie transition of prostate cancer to an advanced, castration-resistant phenotype. These research themes emphasize studies of somatic structural and sequence alterations in the AR gene and their impact on androgen receptor expression patterns, transcriptional activity and hormonal responsiveness of prostate cancer.
	Tobias Else, MD Associate Professor, Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI, USA Dr Else’s clinical and research focus is on benign and malignant adrenal tumors and hormone excess syndromes, with a specific focus on patients with hereditary cancer syndromes. He pursued his clinical training at the University of Hamburg and the University of Michigan. His clinical practice focuses on the care for patients with benign and malignant endocrine tumors, particularly pheochromocytoma, adrenocortical tumors and neuroendocrine tumors as well as accompanying hormone excess syndromes. Dr Else has a particular interest in taking care of patients with hereditary syndromes that predispose to the development of endocrine tumors, including diagnosis and ongoing surveillance care. Dr Else also has a long-standing interest in clinical practice guidelines and is the Program Director of the Endocrine Fellowship at the University of Michigan.
	Hannelore Heemers, PhD Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, OH, USA Hannelore Heemers is Associate Staff/Professor at the Department of Cancer Biology of the Cleveland Clinic’s Lerner Research Institute. As a translational scientist, her major research interests are the genomic mechanisms and the signal transduction that drive the progression of prostate cancer towards the lethal stage, with a special interest for the molecular machinery by which the androgen receptor controls prostate cancer target gene expression responsible for aggressive disease progression.
	Hans (J) Hofland, MD, PhD Consultant Endocrinologist and Clinician Scientist, Erasmus Medical Center, Rotterdam, the Netherlands Dr Hofland's clinical practice concentrates on endocrine oncology, particularly neuroendocrine tumor patients. He is the current medical lead for peptide receptor radionuclide therapy in Rotterdam. His key research interests are to discover novel biomarkers and improve therapeutic options for neuroendocrine tumors, with a particular focus on hormonal syndromes and radionuclide therapy. Following his PhD and post-doctoral projects Dr Hofland also has ongoing research interests in steroidogenesis and steroid-dependent cancers.
	Lawrence S Kirschner, MD, PhD Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University Wexner Medical Center/James Cancer Hospital and Solove Research Institute, Columbus, OH, USA Dr Kirschner is a physician scientist who maintains an active clinical practice in the area of adrenal diseases, including both benign and malignant adrenal tumours. He is an active clinical researcher and has participated in clinical trials of new agents for adrenal and pituitary diseases, including adrenal cancer and Cushing syndrome. His research laboratory focuses on the genetics of endocrine tumors, using mouse models and in vitro correlates to understand signalling alterations caused by mutations in genes that cause the inherited tumour predispositions Carney Complex, Cowden Syndrome, and Inherited Pheochromocytoma/ Paraganglioma.
	André Lacroix Professor of Medicine, Endocrine Division, Centre Hospitalier de l’Université de Montréal (CHUM), Canada Professor André Lacroix is professor of Medicine, Endocrine division, Centre hospitalier de l’Université de Montréal (CHUM), Canada. His areas of research include molecular and genetic mechanisms of adrenal tumors and hyperplasias, Cushing’s syndrome and primary aldosteronism. Role of aberrant hormone receptors in adrenal overfunction. New drugs in the therapy of Cushing’s disease, primary aldosteronism, adrenocortical cancer and pheochromocytomas. He has served as Chairman of the Department of Medicine and of Medical and Academic Affairs at CHUM, President of the Canadian Society of Endocrinology and Metabolism and is immediate past Chair of the International Society of Endocrinology.
	Kate E Lines, PhD Radcliffe Department of Medicine, University of Oxford, UK Dr Lines’s primary interests are in the epigenetics of endocrine cancers, particularly tumours occurring as part of the Multiple Endocrine Neoplasia Type 1 (MEN1) syndrome. Her research predominately focuses on using in vitro and in vivo models to identify the epigenetic mechanisms causing pituitary and pancreatic neuroendocrine tumours, and using this information to develop new diagnostic approaches and therapies. She is also the Science Convenor for the Endocrine Cancer Society for Endocrinology network.
	Ann McCormack, PhD Head, Hormones and Cancer Group, Garvan Institute of Medical Research; Senior Staff Specialist, Department of Endocrinology, St Vincent’s Hospital, Sydney, Australia Associate Professor McCormack graduated in 2000 from the University of Sydney, Australia. Following postgraduate training she completed a PhD examining the role of chemotherapy and genetic biomarkers in the management of aggressive pituitary tumours. In 2010 she completed a clinical and research fellowship in the Oxford Centre for Diabetes, Endocrinology and Metabolism, with a focus on pituitary tumours. She was then appointed to her current position as senior staff specialist in the Department of Endocrinology at St Vincent’s Hospital in 2011, and also heads The Hormones and Cancer Group at the Garvan Institute of Medical Research. Her primary research interests are in exploring the biology and new treatment options for aggressive pituitary tumours. She also has research interests in pituitary tumour genetics. As a member for the European Society of Endocrinology’s Taskforce on Aggressive Pituitary Tumours, she was integral to the development of guidelines on the management of aggressive pituitary tumours published in 2017. She chairs the Sydney Pituitary Collaborative Group (SPCG) and Australia New Zealand Pituitary Alliance (ANZPA). She is President-Elect of the Endocrine Society of Australia and board member of the International Pituitary Society.
	Yasuhiro Miki, DVM, PhD Lecturer, Disaster Obstetrics and Gynecology, International Research Institute of Disaster Science (IRIDeS), Tohoku University, Japan His major research interests are on the endocrine action and metabolism in breast and endometrial cancers, particularly on the intracrine actions of estrogen, androgen, and glucocorticoid in cancer microenvironment. He is also working on revealing hormone-dependent behaviors of lung cancer.
	Patrick Petrossians MD, PhD Chief of Clinic, Endocrinology, University Hospital, Liège, Belgium Dr Petrossians graduated in medicine from the University of Liège in 1991 and in internal medicine and endocrinology in 1996. He is Chief of Clinic at the university hospital of Liège (CHU de Liège) in Belgium and 'Chargé de cours adjoint' at the University of Liège. His main research and publication field has been on neuroendocrinology and pituitary disease but he has also published an atlas of thyroid ultrasound imaging. Apart from his clinical practice, he is also involved in IT and data mining in the field of endocrinology. He is past president of the Belgian Endocrine Society (BES) and the treasurer of the European Neuroendocrine Association (ENEA).
	Gail S Prins, PhD Michael Reese Professor of Urology, Pathology and Physiology, College of Medicine; Professor of Environmental Health Sciences, School of Public Health; Co-Director, Chicago Center for Health and Environment, University of Illinois at Chicago, USA Dr Gail Prins’ research is focused on hormonal regulation of prostate gland development and carcinogenesis. Current areas of emphasis include estrogen actions in the prostate, human prostate stem and progenitor cells, the influence of early life exposures to endocrine disrupting chemicals and toxins on adult prostate cancer risk and molecular underpinnings of prostate cancer disparities in African-American men. Dr Prins is a Past-President of the Society for Basic Urologic Research (SBUR) and the American Society of Andrology (ASA) and has received multiple awards including the 2020 Presidential Citation Award from the American Urologic Association (AUA), the 2019 SBUR Distinguished Service Award, and the 2014 ASA Distinguished Andrologist Award.
	Cristina L Ronchi, MD, PhD Clinician Scientist in Endocrine Oncology and Consultant in Endocrinology, Institute of Metabolism and System Research, University of Birmingham, UK Dr Ronchi is an Endocrinologist and Clinician Scientist with long-standing expertise in endocrine tumors. She obtained her Medical Degree, Specialisation in Endocrinology & Diabetes and PhD in Endocrine Sciences at the University of Milan (Italy). From 2010 to 2017, she worked at the University Hospital of Würzburg (Germany), where she led the section “Translational Tumor Endocrinology”. Since January 2018, she is Senior Lecturer at the Institute of Metabolism and System Research in Birmingham (UK). Her research field focuses on molecular markers involved in the pathogenesis and prognosis of adrenocortical neoplasia. Dr Ronchi is particularly active in research dissemination and collaborates with world-leading groups around Europe. She has published more than 80 peer-reviewed journal articles. She is a member of four scientific societies and acts as peer-reviewer for journals, grants and conferences. Dr Ronchi is clinically active as Consultant in Endocrinology at the Queen Elizabeth Birmingham Hospital. She is coordinating multicentre projects on behalf of the European Network for the Study of Adrenal Tumours.
	Shigehira Saji, MD, PhD Professor and Chairman, Department of Medical Oncology, Fukushima Medical University, Japan Professor Saji received an MD degree in 1992 and PhD degree in 1999 from his home town university, Gifu University School of Medicine. After residency at Tokyo Metropolitan Komagome Hospital, he accumulated his basic and clinical research experience at Saitama Cancer Center Research Institute, Karolinska Institute and M.D. Anderson Cancer Center. Prior to his current appointment, he was chief physician of Tokyo Metropolitan Komagome Hospital (2001-2009), associate professor of Saitama Medical University (2009-2011) and of Kyoto University. His main areas of research include basic biology of hormone-dependent breast cancer and translational/clinical research related to endocrine therapy and immune therapy.
	Renea Taylor, PhD Deputy Head of the Cancer Program, Biomedicine Discovery Institute; Research Fellow, Department of Physiology, Monash University, Australia Associate Professor Renea Taylor’s research interests centre around hormone-dependent cancers, particularly prostate cancer. Her studies focus on dissecting appropriate cellular targets in cancer, including stromal cells and stem cells, and subsequently identifying novel therapeutic strategies to treat prostate cancer. More recently, her team has focused on elucidating the endocrine and metabolic changes that contribute to prostate cancer disease progression, including fatty acid metabolism. She is the past Program Convener of the Endocrine Society of Australia (ESA) and has been awarded the Servier Award, the Novartis Award and the Australian Women in Endocrinology Investigator Award from the ESA.
	Marily Theodoropoulou, PhD Associate Professor of Neuroendocrinology, Department of Endocrinology, Ludwig Maximilian University Clinic, Munich, Germany Marily Theodoropoulou's research focuses on the pathogenesis and management of pituitary tumours. She is particularly interested in identifying, delineating and targeting deregulated signalling cascades responsible for pituitary tumour formation and treatment resistance. She has published more than 75 papers in peer-reviewed journals. She is currently member of the executive committee of the Neuroendocrine Section of the German Society for Endocrinology and the Basic Lead of the European Society of Endocrinology Focus Area 'Pituitary and Neuroendocrinology'.
	Nicole Unger, MD Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, Germany Nicole Unger is Deputy Head of the European Neuroendocrine Tumour Society (ENETS) Centre of Excellence at the University Hospital Essen. She also heads the Endocrine Transfer Program Essen, coordinating the transition from paediatric to adult endocrine care. Her major areas of interest are neuroendocrine, pituitary and adrenal tumours as well as endocrine late effects in childhood cancer survivors.
	Maria Chiara Zatelli MD, PhD Professor of Endocrinology at the University of Ferrara and Head of the Endocrine Unit at the University Hospital in Ferrara, Italy Professor Zatelli’s major research interests are neuroendocrine, thyroid and pituitary tumors, both from the clinical and the translational point of view, focussing on prognostic factors and resistance to medical treatment. She is a member of several international and Italian national societies. Professor Zatelli is currently the Secretary of the European Neuroendocrine Association and actively collaborates with the European Society for Endocrinology.